Viatris sues Novo Nordisk over generic Wegovy patent dispute
Viatris has initiated legal proceedings against Novo Nordisk in a Delaware federal court, asserting that its anticipated generic version of Wegovy does not infringe upon the patent rights of the Danish company. Mylan Pharmaceuticals, which is a subsidiary of Viatris, submitted a request to the court on Thursday, seeking a ruling that their generic product would not breach Novo Nordisk's patent for the method of administering single-dose Wegovy pens for weight loss.
Last year, Novo Nordisk amassed approximately $31 billion in revenue from its semaglutide-based weight loss medications, Wegovy and Ozempic, as per company disclosures. Regulatory guidelines stipulate that generic versions of Wegovy and Ozempic cannot be introduced into the U.S. market until 2032, which corresponds to the expiration of Novo Nordisk's patents encompassing semaglutide, the active ingredient in the drugs.
Previously, Novo Nordisk has reached settlements in patent disputes concerning proposed generics of Wegovy and Ozempic with Mylan and other pharmaceutical entities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
